Lead product focus Candel is advancing CAN-2409 as a lead candidate in multiple localized solid tumor settings (localized prostate cancer, NSCLC, pancreatic cancer) with ongoing Phase 2/3 trials, signaling a primary commercial opportunity in prostate cancer and potential expansion to adjacent solid tumors.

Commercial partnerships Strategic collaborations are already in place or imminent, including a commercialization agreement with EVERSANA to support US launch readiness for CAN-2409, indicating a clear path to market access, payer engagement, and field force orchestration.

Manufacturing readiness Candel is actively enabling scalable manufacturing for CAN-3110 via Batavia’s HIP-Vax platform, suggesting capacity to meet future demand for HSV-based immunotherapies and potential cross-platform fill/contract manufacturing opportunities.

Leadership and advisory Recent senior appointments and advisory board additions (chief commercial officer hire and immunology expert on the RAB) point to a strengthened go-to-market strategy and scientific credibility that can accelerate market adoption and stakeholder engagement.

Financial and fundraising signals With a revenue range and a substantial funding cushion plus a royalty facility, Candel has financial continuity to support early commercial readiness, payer negotiations, and milestone-driven partnerships pivotal for sales efforts.